Just weeks before a big conference, new real-world data confirmed that EKOS, an embolization product from Boston Scientific, was safer than its leading competitor. This was good news under regular circumstances. Great news, given the competitor was traipsing around town claiming superiority. We created a campaign that put BSC on the offensive.